Exploring how compounds from hops can help reduce inflammation in bowel diseases.
Discovery and Biological Signatures of Microbiome-Derived Xanthohumol Metabolites and their Role in Ameliorating Inflammatory Bowel Disease
This study is looking at how a natural compound from hops called xanthohumol might help reduce inflammation in people with inflammatory bowel disease (IBD) by working with gut bacteria, and patients may be asked to provide samples to help us learn more about this process.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Oregon State University NIH-funded |
| Lab location | 1 site (Corvallis, United States) |
| Project ID | NIH-10237375 on NIH RePORTER |
What this research studies
This research investigates the potential of xanthohumol, a compound found in hops, to alleviate inflammation in patients with inflammatory bowel disease (IBD). The study focuses on how xanthohumol is metabolized by gut bacteria and how these metabolites may contribute to reducing gut inflammation. By examining the interactions between xanthohumol, gut microbiota, and the inflamed intestine, the researchers aim to identify biological signatures that could lead to new therapeutic approaches for IBD. Patients may be involved in providing samples to help understand these interactions better.
Who could benefit from this research
Good fit: Ideal candidates for participation are adults aged 21 and older who are diagnosed with inflammatory bowel disease, such as Crohn's disease or ulcerative colitis.
Not a fit: Patients with inflammatory bowel disease who are not responsive to dietary changes or those who have other underlying conditions unrelated to gut inflammation may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that effectively reduce inflammation and improve the quality of life for patients with inflammatory bowel disease.
How similar studies have performed: Previous research has shown promising results with similar approaches using dietary compounds to modulate gut inflammation, suggesting potential for success in this study.
Where this research is happening
Corvallis, United States
- Oregon State University — Corvallis, United States (Active)
Researchers
- Principal investigator: Stevens, Jan Frederik — Oregon State University
- Study coordinator: Stevens, Jan Frederik
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.